HDM1002 / Huadong Medicine - LARVOL DELTA

A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial • Hepatology

HDM1002 in Chinese Adults with Overweight or Obesity—A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • P1 data • Metabolic Disorders • Obesity

Huadong Medicine: HDM1002 is expected to start Phase III clinical study for weight management indication in the country this month [Google translation] (Eastmoney.com) - "Huadong Medicine(000963.SZ) stated on the investor interaction platform on March 12 that HDM1002 is expected to start Phase III clinical research for weight management indications in China this month."

New P3 trial • Obesity

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults (clinicaltrials.gov) - P3 | N=780 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P3 trial • Genetic Disorders • Obesity

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial • Obesity

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial

A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial • Obesity

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P2 trial • Genetic Disorders • Obesity

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=318 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity (EASD 2023) - "In summary, we roport the preclinical data of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist administered in participants with T2D. HDM1002 had a favorable safety and tolerability profile, which was generally consistent with the peptidic GLP-1R agonist class. The results of this study support further clinical development of HDM1002 for the treatment of T2D and obesity."

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

The “magic drug for weight loss” has become the king of European market capitalization, competition among Chinese pharmaceutical companies has accelerated, and 8 generic drugs have been clinically accepted during the year [Google translation] (36Kr) - "...Huadong Medicine...announced that the clinical trial application for HDM1002 tablets submitted by its wholly-owned subsidiary Sino-American Huadong was approved by the National Medical Products Administration (NMPA). According to the announcement, the drug is an oral small molecule GLP-1 receptor agonist, and its indication is for weight management in overweight or obese people."

New trial • Metabolic Disorders • Obesity